In summary, existing data suggest that breast cancers, which are ER-negative and overexpress both HER2 and COX-2, may have a more prominent Akt pathway activation, increased resistance to apoptosis, and a higher metastatic potential, which is all consistent with the findings in this study. The gene discussed is PTGS2; the disease is breast carcinoma.